2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W017018S4
    L-Ornithine-d7 hydrochloride 2483831-57-6 99.90%
    L-Ornithine-d7 (hydrochloride) is the deuterium labeled L-Ornithine hydrochloride. L-Ornithine hydrochloride is a free amino acid that plays a central role in the urea cycle and is also important for the disposal of excess nitrogen.
    L-Ornithine-d7 hydrochloride
  • HY-Y0319G
    Magnesium acetate tetrahydrate 16674-78-5 99.47%
    Magnesium acetate tetrahydrate is a carboxylic acid and short-chain fatty acid (SCFAs). Magnesium acetate tetrahydrate activates AMPK, increases ROS, cleaved caspase 9, PPARα, downregulates SREBP-1c, ChREBP expression. Magnesium acetate tetrahydrate exhibits antifungal activity against Saccharomyces cerevisiae W303-1A. Magnesium acetate tetrahydrate regulates energy metabolism. Magnesium acetate tetrahydrate has anticancer activity against gastric cancer. Magnesium acetate tetrahydrate induces writhing reaction and ulcerative colitis. Magnesium acetate tetrahydrate can be used in the researches for gastric cancer, ulcerative colitis, hepatic steatosis, and pain.
    Magnesium acetate tetrahydrate
  • HY-14153
    Tegaserod 145158-71-0 99.71%
    Tegaserod is an orally active serotonin receptor 4 (HTR4; 5-HT4R) agonist and a 5-HT2B receptor antagonist. Tegaserod has pKis of 7.5, 8.4 and 7.0 for human recombinant 5-HT2A, 5-HT2B and 5-HT2C receptors, respectively. Tegaserod causes tumor cell apoptosis, blunts PI3K/Akt/mTOR signaling and decreases S6 phosphorylation. Tegaserod has anti-tumor activity and has the potential for irritable bowel syndrome (IBS) research.
    Tegaserod
  • HY-15981
    Omarigliptin 1226781-44-7 99.96%
    Omarigliptin (MK-3102) is a potent, selective, orally active and cross the blood-brain barrier dipeptidyl peptidase 4 (DPP-4) inhibitor. Omarigliptin shows anti-parkinsonian activity. Omarigliptin has the neuroprotective effect to improve diabetes-associated cognitive dysfunction.
    Omarigliptin
  • HY-105185
    Fidarestat 136087-85-9 99.63%
    Fidarestat (SNK 860) is an inhibitor of aldose reductase, with IC50s of 26 nM, 33 μM, and 1.8 μM for aldose reductase, AKR1B10 and V301L AKR1B10, respectively; Fidarestat (SNK 860) has the potential to treat diabetic disease.
    Fidarestat
  • HY-159642
    Dabogratinib 2800223-30-5 99.90%
    Dabogratinib (TYRA-300) is an orally active, selective FGFR3 inhibitor with an IC50 of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia.
    Dabogratinib
  • HY-131703
    UGT8-IN-1 2414349-93-0 99.94%
    UGT8-IN-1 is a brain penetrable and orally active inhibitor of ceramide galactosyltransferase enzyme (UGT8). UGT8-IN-1 can be used in the study for lysosomal storage disorders.
    UGT8-IN-1
  • HY-B2194
    γ-Oryzanol 11042-64-1 99.66%
    γ-Oryzanol is a potent DNA methyltransferases (DNMTs) inhibitor in the striatum of mice. γ-Oryzanol significantly inhibits the activities of DNMT1 (IC50=3.2 μM), DNMT3a (IC50=22.3 μM).
    γ-Oryzanol
  • HY-N0404
    Sinigrin 3952-98-5 99.97%
    Sinigrin (Allyl-glucosinolate) is an orally active glucosinolate found in cruciferous plants. Sinigrin possesses multiple activities such as anti-cancer, antibacterial, antifungal, anti-inflammatory, antioxidant, and inhibition of fat synthesis. Sinigrin can be used in the research of tumors, inflammatory, and metabolic diseases.
    Sinigrin
  • HY-N0704
    Agrimol B 55576-66-4 ≥98.0%
    Agrimol B, a polyphenol, is an orally active and potent SIRT1 activator. Agrimol B shows anti-adipogenic and anticancer activity. Agrimol B shows antibacterial activity against plant pathogens. Agrimol B dramatically inhibits 3T3-L1 adipocyte differentiation by reducing PPARγ, C/EBPα, FAS, UCP-1, and apoE expression. The action of Agrimol B on the cancer cells is likely derived from its effect on c-MYC, SKP2 and p27.
    Agrimol B
  • HY-N0761
    Isoferulic acid 537-73-5
    Isoferulic acid (3-Hydroxy-4-methoxycinnamic acid) is an orally active cinnamic acid derivative. Isoferulic acid exhibits hypoglycemic, antiviral, and antioxidant activities. Isoferulic acid can also inhibit fructose- and glucose-mediated protein glycation. Isoferulic acid can be used in the research of diseases such as diabetes.
    Isoferulic acid
  • HY-N1063
    Xanthoxylin 90-24-4 99.84%
    Xanthoxylin (Xanthoxyline) can be isolated from Zanthoxylum simulans. Xanthoxylin has antifungal and antioxidant effects. The MIC of Xanthoxylin against Toxoplasma neonatorum and Aspergillus fumigatus were 50 µg/mL and 75 µg/mL, respectively. Xanthoxylin can be used in the study of anti-epileptic diseases.
    Xanthoxylin
  • HY-P1514
    Peptide YY (PYY), human 118997-30-1 99.17%
    Peptide YY (PYY) is a gut hormone that regulates appetite and inhibits pancreatic secretion. Peptide YY (PYY) can mediate its effects through the Neuropeptide Y receptors.
    Peptide YY (PYY), human
  • HY-P2803
    Beta-glucuronidase (Escherichia coli) 9001-45-0
    Beta-glucuronidase is a glycosyl hydrolase that hydrolyzes β-glucuronic acid and sulfate esters in urine and other biological fluids, and then releases β-glucuronate.
    Beta-glucuronidase (Escherichia coli)
  • HY-Y1667
    2,6-Dibromophenol 608-33-3 ≥98.0%
    2,6-Dibromophenol (2,6-DBP) is a weak inhibitor targeting voltage-gated Ca2+ channels. 2,6-Dibromophenol has no significant effect on potassium-induced calcium elevation in PC12 cells. 2,6-Dibromophenol shows a 48 h EC50 of 2.78 mg/L for Daphnia magna and a 96 h EC50 of 9.90 mg/L for algae (Scenedesmus quadricauda).
    2,6-Dibromophenol
  • HY-113371
    2-Methylcitric acid 6061-96-7
    2-Methylcitric acid (Methylcitric acid) is an endogenous metabolite in the 2-methylcitric acid cycle. 2-Methylcitric acid accumulates in methylmalonic and propionic acidemias and acts as a marker metabolite. 2-Methylcitric acid markedly inhibits ADP-stimulated and uncoupled respiration in mitochondria supported by glutamate.
    2-Methylcitric acid
  • HY-117656
    ESI-05 5184-64-5 99.78%
    ESI-05 is a specific exchange proteins directly activated by cAMP 2 (EPAC2) inhibitor. ESI-05 inhibits cAMP-mediated EPAC2 GEF activity with an IC50 of 0.43 μM. ESI-05 can be used for the research of diabetes, insulin secretion and neurological disorders.
    ESI-05
  • HY-125588
    Chromium picolinate 14639-25-9 99.76%
    Chromium picolinate (Chromium (III) picolinate) is a compound that has oral activity. Chromium picolinate induces apoptosis. Chromium picolinate is the activator of p38 MAPK. Chromium picolinate has antioxidant activity. Chromium picolinate can be used in research on type 2 diabetes.
    Chromium picolinate
  • HY-163316
    SIRT4-IN-1 3030697-87-8 99.94%
    SIRT4-IN-1 is a selective and potent Sirtuin 4 (Sirt4) inhibitor with an IC50 of 16 μM for hSirt4. SIRT4-IN-1 also inhibits hSirt1, hSirt2, hSirt3, hSirt4 and hSirt6. SIRT4-IN-1 competes with acyl peptide substrate for Sirt4's acyl binding site, and is noncompetitive with NAD+. SIRT4-IN-1 increases glutamate dehydrogenase (GDH) activity and rescues pyruvate dehydrogenase (PDH) activity. SIRT4-IN-1 inhibits adipocyte differentiation and suppresses Sirt4 overexpression-induced increased differentiation. SIRT4-IN-1 can be used for the researches of cancer and metabolic disease.
    SIRT4-IN-1
  • HY-P10000
    Peptide YY (PYY) (3-36), Human 123583-37-9 98.00%
    Peptide YY (PYY) (3-36), Human is an endogenous appetite suppressing peptide. Peptide YY (PYY) (3-36), Human, a neuropeptide Y (NPY) Y2 receptor agonist, is a powerful inhibitor of intestinal secretion.
    Peptide YY (PYY) (3-36), Human
Cat. No. Product Name / Synonyms Application Reactivity